Search page

A Phase 3 Open-Label Trial-In-Progress Evaluating Garadacimab For Prophylactic Treatment Of Pediatric Patients (Aged 2–11 Years) With Hereditary Angioedema

A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis

A randomized, double-blind, phase 2a study of covalent Bruton’s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines

Activation-induced marker (AIM) assay to study allergic skin reactions: a case study on p-phenylenediamine

Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Gene Expression and Protein Levels in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study

Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from a Phase 1b/2a Study

CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks

CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study

Comparative phase 2 bioavailability study of a fast acting, dry powder-based, epinephrine intra-nasal formulation, FMXIN002, for anaphylaxis

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)

Dupilumab Improves Small Airway Dysfunction in Patients With Moderate-to-Severe Asthma: The Phase 4 VESTIGE Study

Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab normalized the esophageal transcriptome in children aged 1 to <12 years with eosinophilic esophagitis (EoE) in the Phase 3 EoE KIDS trial

Effect of Remibrutinib on Disease Activity in Patients with Chronic Spontaneous Urticaria: Post Hoc Analysis of Phase 3 REMIX-1 and REMIX-2 studies

Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 Studies

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design

Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H1-Antihistamine Treatment

Long-Term Durability of CRISPR-Based Gene Editing of KLKB1 From Phase 1 of a Phase 1/2 Trial of Patients With Hereditary Angioedema

Long-Term Efficacy and Safety of Remibrutinib in Patients with Chronic Spontaneous Urticaria in the Phase 3 REMIX-1 and REMIX-2 Studies

Long-Term Efficacy and Safety of Stapokibart in Patients with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Pivotal Phase 3 Trial

Long-term efficacy of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis

Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis

Objective and Subjective Sleep Assessments in Patients With Atopic Dermatitis Treated With Dupilumab: Results From DUPISTAD, a Phase 4 Randomized Placebo-Controlled Study

Oral Sebetralstat for On-demand Treatment of Hereditary Angioedema: Phase 3 KONFIDENT Trial Results

Phase 2 Study to Evaluate the Sensitivity, Specificity, and Safety of DBV1605 as a Diagnostic Tool for Non–IgE-Mediated Cow’s Milk Allergy in Children (APTITUDE)

Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system

Primary and Safety Outcomes of a Phase 3, Open-Label, Single-Arm, 12-Week Study of Treatment with PI3Kδ Inhibitor Leniolisib in Paediatric Patients Aged 4–11 Years With Activated PI3Kδ Syndrome (APDS)

Prospective, pilot, phase 1 study of iPUMP© in patients starting sublingual allergen immunotherapy (Staloral©)

Rapid Symptom Resolution in Oral Allergy Syndrome Following Anaphylm Administration: A Phase 2 Study Update

Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Real-world evidence study on the effectiveness and safety of lanadelumab in France: the SERENITI study

Reduction in Weekly Urticaria Activity Score (UAS7) With Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies

Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies

Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Retrospective Evaluation of Patients Diagnosed with Childhood (Cutaneous) Mastocytosis: Türkiye Childhood Mastocytosis Study Group Multicenter Study

Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study

Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies

Secondary endpoint profile is strongly supportive for the positive outcome of the pivotal Phase III study with PQ Grass

Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial

Study design for A multicenter, open label, randomized Study to inveStigate the effIcacy of Subcutaneous immunoTherapy combined with vitamin D3 in children and adolescent patients with allergic rhinitis (ASSIST study)

Study design for the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders: a multicenter prospective observational study (CALM study)

Study design for the efficacy of AIT in children with mild attention deficit hyperactivity disorder complicated with HDM allergy: a prospective observational study

Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study

The BEACON Study: A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of the c-Kit Mab Briquilimab in Adults with symptomatic Chronic Spontaneous Urticaria (CSU)

The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomised, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps

Baseline Demographics and Disease Characteristics of Pediatric Patients with Eosinophilic Esophagitis (EoE) from the Randomized, Placebo-Controlled, Phase 3 EoE KIDS Study

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study

Dupilumab Is Efficacious in Children Aged 1–11 Years Weighing ≥15 kg With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study

Dupilumab efficacy in patients with an inadequate response, intolerance, or contraindication to swallowed topical corticosteroids: a subgroup analysis of data from the phase 3 LIBERTY EoE TREET study

Dupilumab improves histologic and endoscopic outcomes in children aged 1–11 with eosinophilic esophagitis: Results from Part A of the Phase 3 EoE KIDS study

Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps overall and in patients with and without co-morbid asthma: results from the phase 3 WAYPOINT study

Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Subanalysis of the Phase 3 OASIS-HAE Study

Garadacimab improves quality of life in patients with hereditary angioedema: Results from the Phase 3 open-label extension study

Long-term safety of donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 open-label extension OASISplus study

Self-reported treatment preferences of patients switching from prior prophylactic therapies to donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 OASISplus study

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Event Resources

Sponsored Symposia

Website

Sessions